# OnCo record manifest-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/manifest-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "manifest-2", "NCT04603495" ;
  schema:name "MANIFEST-2"@en ;
  schema:description "MANIFEST-2 found that adding the BET inhibitor pelabresib to ruxolitinib shrank spleens in nearly twice as many people with myelofibrosis, but the improvement in symptoms did not reach statistical significance, leaving the drug's approval uncertain."@en ;
  schema:url <https://onco.cc/trials/manifest-2/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04603495> ;
  onco:status "mixed" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/primary-myelofibrosis/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:drugs <https://onco.cc/drugs/pelabresib/>, <https://onco.cc/drugs/ruxolitinib/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/morphosys/> ;
  onco:people <https://onco.cc/people/raajit-rampal/> .